Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00429312 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma

StatusCompleted
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Results first posted: Jul 27, 2026 Primary endpoint revised · Start date: Mar 2007 to Feb 2007 · Secondary endpoints revised (4) · 1 morev13 Show 4 more changesShow less
    • Primary endpoint revised
    • Start date: Mar 2007 to Feb 2007
    • Secondary endpoints revised (4)
    • Study sites revised (3)

    See this version in full on ClinicalTrials.gov ↗

  2. Study arms: 0 to 1v12
  3. Re-verified, no change to tracked fieldsv11
  4. Enrollment target: 15 to 10 Primary completion date: Dec 2009 to Feb 2008 · Start date: Feb 2007 to Mar 2007v10 Show 2 more changesShow less
    • Primary completion date: Dec 2009 to Feb 2008
    • Start date: Feb 2007 to Mar 2007
  5. 3 versions Re-verified since Sep 2, 2011, no change to tracked fieldsv7-v9
Show 5 earlier versionsHide 5 earlier versions
  1. Primary and study completion dates changed from estimate of Dec 2008 to Dec 2009 Trial status: Suspended to Completedv6 Show 1 more changeShow less
    • Trial status: Suspended to Completed
  2. Trial status: Recruiting to Suspended Sponsor's reason: Enrollment paused for interim data analyis Primary completion date: Dec 2008 · Completion date: Jun 2008 to Dec 2008 · Interventions: Recombinant vaccinia virus (TK-deletion plus GM-CSF) (Genetic) to JX-594 (Biological) · 2 morev5 Show 5 more changesShow less
    • Primary completion date: Dec 2008
    • Completion date: Jun 2008 to Dec 2008
    • Interventions: Recombinant vaccinia virus (TK-deletion plus GM-CSF) (Genetic) to JX-594 (Biological)
    • Secondary endpoints: details revised at 4 of 4 entries
    • Site details revised at 3 of 3 sites
  3. Study sites: 1 to 3 Completion date: Apr 2008 to Jun 2008 · Secondary endpoints: details revised at 1 of 4 entriesv4 Show 2 more changesShow less
    • Completion date: Apr 2008 to Jun 2008
    • Secondary endpoints: details revised at 1 of 4 entries
  4. Re-verified, no change to tracked fieldsv3
  5. Trial status: Not Yet Recruiting to Recruiting Site details revised · Study title shortened, about 2 wordsv2 Show 2 more changesShow less
    • Site details revised
    • Study title shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this research study is to find out whether JX-594 (Pexa-Vec) is safe and effective for treating surgically unresectable malignant melanoma.
Trial Details
NCT Number NCT00429312
Lead Sponsor Jennerex Biotherapeutics
Conditions Melanoma
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov